Cutaneous reactions to COVID-19 vaccines: A review

See Wei Tan, MBBS, MRCP, Yew Chong Tam, BSc, and Shiu Ming Pang, MBBS, Dip Dermatology (London), MRCP (UK)

Singapore, Singapore

Background: The increasing number of reports on cutaneous reactions following COVID-19 vaccination has led to growing concerns among certain groups.

Objective: We reviewed the published reports of cutaneous lesions after COVID-19 vaccination.

Methods: We conducted a literature search for original and review articles published between January 1, 2020, and September 27, 2021.

Results: Eleven cutaneous reactions associated with COVID-19 vaccines were determined; the most prevalent reactions were local injection site reactions, delayed local reactions, urticaria, angioedema, and morbilliform eruptions. There were more reports on skin reactions following the administration of messenger RNA-based vaccines than on those following the administration of adenoviral vector or inactivated whole-virus vaccines, in part, due to their higher administration rate. Most reported skin reactions occurred after the first vaccine dose.

Limitations: A reporting bias could not be excluded, and skin biopsy results were not available for most included individuals. Moreover, given that the included trials focused on vaccine efficacy, there was a lack of details concerning cutaneous reactions and participant information.

Conclusion: Not all cutaneous reactions observed after COVID-19 vaccination are hypersensitivity reactions. Different cutaneous reactions may reflect underlying immune responses to the vaccines. A large majority of COVID-19 vaccination reactions were mild and self-limiting, and people should be encouraged to complete their vaccination regimen. (JAAD Int 2022;7:178-86.)

Key words: anaphylaxis; angioedema; chilblains; COVID-19; cutaneous reaction; herpes zoster; immunity; injection site reaction; pityriasis rosea; urticaria; vaccination.

INTRODUCTION

As COVID-19 mass vaccination is underway, increasing reports of adverse reactions associated with the vaccines are emerging. Anecdotal reports regarding novel formulations of messenger RNA (mRNA)-based vaccines are being inflated by social media, generating alarming misconceptions about vaccination. Therefore, understanding the spectrum of adverse reactions to COVID-19 vaccines is crucial in creating awareness of the importance of vaccination in the general population.

Although systemic adverse effects are important, cutaneous effects are the immediate reason for dissuading vaccine administration. We reviewed the published reports of cutaneous reactions to COVID-19 vaccines and described these reactions in relation to clinical practice. We reported the prevalence of cutaneous reactions to different types
of COVID-19 vaccines and the clinical severity of the reactions.

MATERIALS AND METHODS

For this review, we searched PubMed, OVID, EMBASE, MEDLINE, and Google Scholar for original and review articles written in English and published from January 1, 2020, to September 27, 2021. We used the key words “cutaneous,” “skin,” “rash,” “morbilliform,” “sweet syndrome,” “pityriasis rosea,” “pityriasis-rosea-like,” “pemphigus,” and “bullous pemphigoid” in combination with “COVID-19 vaccination,” “2019-nCOV,” “novel coronavirus,” “human coronavirus 2019,” “hCoV-19,” and “SARS-CoV-2.” We reviewed the published reports of cutaneous reactions to all COVID-19 vaccines approved by the World Health Organization; we included Gam-COVID-Vac (Sputnik V; Gamaleya National Research Center of Epidemiology, Health Ministry of the Russian Federation) and BBV152 (Covaxin; Bharat Biotech International Ltd), given their global availability. We eliminated articles that were not relevant to cutaneous manifestations (Table I). We extracted the following data from the included studies: skin reactions, type of vaccine, administration dose (first or second dose), median duration between vaccine administration and the eruption of lesions, clinical outcomes, and skin biopsy results (Table I).

RESULTS

We summarized the findings of 75 articles: 7 randomized controlled trials, 1 registry-based study, 1 prospective cohort study, 4 retrospective studies, 21 case series, and 41 case reports. In total, 125,713 patients were included, and 48,740 cutaneous reactions were described (Supplementary Table I, available via Mendeley at https://data.mendeley.com/datasets/vbjbr7ynh/1).

The median age of individuals in whom cutaneous reactions developed after COVID-19 vaccination was 49.3 years; however, in 99% (48,387/48,740) of the cases, the age was not reported. Among the 48,740 reported cutaneous reactions, 45 (0.1%) occurred in men, 310 (0.6%) occurred in women, and 48,385 (99.3%) did not report their sex. Table I presents these findings. Skin reactions occurred in 28,655 (58.8%) cases after the first dose, 19,987 (41%) cases after the second dose, and 98 (0.2%) cases in which the dose was undocumented.

A total of 213,198 COVID-19 vaccine doses were administered in the included articles; 91,111 doses of mRNA-1273 (Moderna, Inc; National Institute of Allergy and Infectious Diseases), 63,030 of BNT162b2 (Comirnaty; Pfizer/BioNTech Manufaturing GmbH and Fosun Pharma), 31,465 of Gam-COVID-Vac, 21,895 of Ad26.COV2.S (Janssen Pharmaceuticals Com-panies of Johnson & Johnson), 2362 of BBIBP-CorV (Sinopharm; China National Biotec Group Co, Ltd and Beijing Institute of Biological Products Co, Ltd), 1798 of Vero cell (CoronaVac; Sinovac Research and Development Co, Ltd), 676 of AZD1222 (ChAdOx1-S; Covishield/Vaxzevria; AstraZeneca and University of Oxford), and 596 of BBV152. However, in 265 cases, the vaccine type was not documented (Table I).

Among the 48,740 reported cutaneous reactions, 38,472 (78.93%) occurred after the administration of mRNA vaccines, 8920 (18.3%) after the administration of adenoviral vector vaccines, and 1333 (2.74%) after the administration of inactivated whole-virus vaccines (Table II). The vaccine name was not recorded in 15 (0.03%) cases. However, taking into consideration the total doses of mRNA vaccines (154,141 doses) and inactivated whole-virus COVID-19 vaccines (4756 doses) administered in the included studies, the prevalence of cutaneous reactions reported with mRNA vaccines (38,472/154,141; 25%) was lower than that with inactivated whole-virus COVID-19 vaccines (1333/4756; 28.3%). Table III provides the details of these findings. Cutaneous reactions occurred more commonly after the first dose (28,655/48,740; 58.8%) than after the second dose (19,987/48,740; 41%).

We classified the most commonly reported cutaneous reactions associated with COVID-19 vaccines into the following 11 classes:

1. Local injection site reactions: Local injection site reactions included pain, redness, and swelling, which occur within 7 days after vaccination.

On average, these reactions started on the first
day after vaccination, regardless of the dose. The median duration of these reactions was 2 to 3 days. These were the most common skin reactions associated with the COVID-19 vaccines (96%). For the 8 vaccines that were studied, the most common local injection site reaction was pain (36,883/48,740; 75.7%), followed by redness (4497/48,740; 9.2%) and swelling (5563/48,740; 11.4%). Most (58.7%) reactions occurred after the first dose. Younger individuals tended to have a higher incidence than older individuals. However, the median age and sex of the individuals were not documented.

2. Delayed local reactions: Delayed local reactions are local reactions with onset at \(7 \text{ days after vaccination} \). These reactions were characterized by erythema, pruritus, induration, tenderness near the injection site, and a presentation mimicking cellulitis, and these accounted for 1.7% of the reported skin reactions. Nearly all the reported delayed local reactions (889/898; 99%) occurred after mRNA vaccination. Most (74.9%) of the delayed local reactions occurred after the first dose. The median age of individuals who experienced these reactions was 51.5 years. The median duration of the onset of delayed local reactions following COVID-19 vaccination was 7 days.

3. Urticaria: Urticaria is characterized by pruritic erythematous wheals or plaques. A total of 440 (0.9%) urticarial reactions were reported. Most (97.9%) of the urticarial reactions occurred after mRNA vaccination. Among 19 individuals for whom the age and sex were documented, the median age was 37.9 years (women: 17/19, 89.5%; men: 2/19, 10.5%). The median duration of the onset of urticarial eruptions following COVID-19 vaccination was 22 hours.

4. Angioedema: Angioedema is characterized by submucosal or subcutaneous swelling. It accounted for 0.5% of the reported skin reactions following COVID-19 vaccination. All the reported cases of angioedema occurred after mRNA vaccination. A total of 50.2% and 49.8% of the angioedema cases occurred after the first and second doses, respectively. Among 3% of cases for which the age and sex were documented, the median age was 40.4 years (women, 6/8, 75%; men: 2/8, 25%). The median duration of the onset of angioedema eruptions following COVID-19 vaccination was 12 hours.

5. Morbilliform eruption: Of the reported skin reactions after COVID-19 vaccination, morbilliform eruption represented 0.09%. All the reported cases occurred after mRNA vaccination. A total of 72% and 28% of the morbilliform eruptions occurred after the first and second doses, respectively. The median age of individuals who reported a morbilliform eruption was 55 years. The median duration of the onset of morbilliform eruptions following COVID-19 vaccination was 3 days.

6. Herpes zoster: Herpes zoster accounted for 0.08% of the reported skin reactions. Most (69.2%) cases occurred after the first dose. The median age of individuals who experienced herpes zoster following COVID-19 vaccination was 60 years. The median duration of the onset of herpes zoster following COVID-19 vaccination was 4 days.

7. Bullous(529,593),(545,603)(539,602),(556,612)(548,611),(564,621)(566,620),(583,630)(576,629),(593,638)(586,637),(603,647)(605,646),(622,655)(624,653),(640,663) eruptions: The reported bullous eruptions included bullous pemphigoid (18/20; 90%), pemphigus vulgaris (1/20; 5%), and bullous fixed drug eruption (1/20; 5%). Bullous eruptions accounted for 0.04% of the reported skin reactions following COVID-19 vaccination. All the reported bullous eruptions occurred after mRNA vaccination, and most (60%) occurred after the first dose. The median age of individuals in whom bullous eruptions developed after COVID-19 vaccination was 79 years (men: 50%; women: 50%). The median duration of the onset of bullous eruptions following COVID-19 vaccination was 7 days.

8. Filler reactions: Filler reactions refer to delayed inflammatory reactions to hyaluronic acid-based fillers. They manifest as erythema, painful induration, tissue hardening, and edema. Filler reactions accounted for 0.04% of the reported skin reactions following COVID-19 vaccination. All the reported filler reactions occurred after mRNA vaccination. In total, 50% occurred after the first dose and 50% after the second dose. The median age of individuals who experienced filler reactions was 47 years; 50% of them were women, whereas 50% did not report their age or sex. The median duration of the onset of filler reactions following COVID-19 vaccination was 1 day.

9. Chilblains: Chilblains accounted for 0.03% of the reported skin reactions. All the reported cases of chilblains occurred after mRNA vaccination, and most (64%) occurred after the first dose. The median age of individuals who experienced chilblains was 70 years. The
|                          | mRNa-based vaccines | Adenoviral vector vaccines | Inactivated whole-virus vaccine |
|--------------------------|---------------------|---------------------------|--------------------------------|
|                          | BNT162b2 mRNA-1273  | Sputnik V Vaxzevria/Covishield Ad26.COV2.S | CoronaVac Covaxin Sinopharm |
| First dose               | Second dose         | First dose                | Second dose                   | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second dose | First dose | Second do
median duration of the onset of chilblains following COVID-19 vaccination was 3 days.

10. Pityriasis rosea: In total, 0.023% of the reported skin reactions following COVID-19 vaccination were attributed to pityriasis rosea. Most (90%) occurred after mRNA vaccination and after the second dose (60%). The median age of individuals who experienced pityriasis rosea was 39 years; among them, 40% were women, 20% were men, and 40% did not report their age or sex. The median duration of the onset of the eruptions of pityriasis rosea following COVID-19 vaccination was 5.5 days.

11. Severe cutaneous adverse reactions (SCARs): SCARs following COVID-19 vaccination were very rare and accounted for 0.004% (2 cases) of the reported skin reactions. Nonetheless, they posed a significant risk of morbidity and mortality in affected patients. The reported SCARs included acute generalized exanthematous pustulosis and Stevens-Johnson syndrome. The 2 reported cases occurred after the administration of adenoviral vector vaccines. The median age of individuals who experienced SCARs was 67 years, and both were men. The median duration of the onset of SCARs following COVID-19 vaccination was 3 days. Both the patients recovered, with no serious sequelae.

Other less-common cutaneous reactions reported following COVID-19 vaccination included erythema multiforme (0.02%), Sweet syndrome (0.012%), dermal hypersensitivity reactions (0.01%), lichen planus (0.006%), papulovesicular eruptions (0.006%), pityriasis rosea-like eruptions (0.004%), generalized annular lesions (0.002%), facial pustular neutrophilic eruptions (0.004%), and flares of underlying autoimmune skin conditions (0.002%). All the cases resolved, without serious sequelae.

DISCUSSION

The increasing number of reports of cutaneous reactions following mRNA vaccination has led to misinformation in the media. Misleading claims arise from relatively short clinical trials and the novel mechanisms of mRNA vaccines. We sought to explore the skin reactions occurring after COVID-19 vaccination.

Local injection site reactions were more commonly observed in younger individuals than in older individuals. To date, no serious sequelae have been reported in individuals with local injection site reactions. By providing proper vaccine guidance, recipients can be mentally prepared for the possible occurrence of cutaneous reactions and, therefore, more likely to complete their second dose.

In observational studies, delayed local reactions were the most commonly reported cutaneous reactions following COVID-19 vaccination. Nearly all of these reactions occurred after mRNA vaccination, with a few occurring after DNA vaccination. The mechanism of these reactions is not fully understood. The skin biopsy results of these individuals support the speculation of T-cell–mediated hypersensitivity as the mechanism of delayed injection site reactions. Delayed hypersensitivity reactions are expected to occur sooner and more robustly after the second vaccine dose than after the first dose owing to prior sensitization. However, most delayed local reactions to the first dose did not recur with the second dose.

Another hypothesis is related to the delayed appearance of the spike protein; mRNA vaccines require the translation of their mRNA to generate endogenously produced viral spike proteins to which the immune response is generated. Similarly, antigen production in adenoviral vector-based vaccines is delayed because the vaccine is delivered within a viral envelope, and host cells start producing spike proteins in a manner similar to that after the administration of an mRNA vaccine. The immune response generated after the first dose can moderate the subsequent reaction to the second dose. The timing of a delayed local reaction onset coincides with that of the immune system's detection of the spike protein generated by the vaccine's mRNA at the injection site. Delayed local reactions to COVID-19 vaccines may reflect the protective immune

| Table II. Prevalence of cutaneous reactions following COVID-19 vaccination |
|-------------------------------------------------|-----------------|-----------------|----------------|
| Reported cutaneous reactions                        | 38,472          | 8920            | 1333           |
| Total vaccine doses given                           | 154,141         | 54,036          | 4756           |
| Prevalence of cutaneous reactions                   | 38,472/154,141 = 25% | 8920/54,036 = 16.5% | 1333/4756 = 28.3% |

Fifteen reported cases of cutaneous reactions did not have their types of vaccines recorded.
Table III. Summary of the 10-most common cutaneous reactions to COVID-19 vaccines and survival data

| Cutaneous reactions                  | Number of reported reactions | Vaccine name                          | Dose          | Median age, y | Sex    | Clinical outcome                  |
|-------------------------------------|-----------------------------|---------------------------------------|---------------|---------------|--------|-----------------------------------|
| Local injection site reactions      | 46,943                      | BNT162b2: 6895 mRNA-1273: 29,808     | Dose 1: 27,533 | NR            | NR     | No serious sequelae reported     |
|                                     |                             | Covishield/Vaxzevria: 157             | Dose 2: 19,348 |               |        |                                   |
|                                     |                             | Ad 26.COV2.S: 8757                   | NR: 62        |               |        |                                   |
|                                     |                             | CoronaVac: 116                        |               |               |        |                                   |
|                                     |                             | Covaxin: 13                          |               |               |        |                                   |
|                                     |                             | Sinopharm: 1197                      |               |               |        |                                   |
|                                     |                             | BNT162b2: 118 mRNA-1273: 771         | Dose 1: 669   | 51.5          | 7 M: 128 F | No serious sequelae reported     |
|                                     |                             | Covishield/Vaxzevria: 1              | Dose 2: 222   |               | 763 NR |                                   |
|                                     |                             | NR: 8                                | NR: 8         |               |        |                                   |
|                                     |                             | BNT162b2: 88 mRNA-1273: 345          | Dose 1: 205   | 34.5          | 3 M: 16 F | No serious sequelae reported     |
|                                     |                             | CoronaVac: 7                         | Dose 2: 232   |               | 421 NR |                                   |
|                                     |                             |                                         | NR: 3         |               |        |                                   |
|                                     |                             | BNT162b2: 45 mRNA-1273: 232          | Dose 1: 135   | 42.5          | 2 M: 6 F | No serious sequelae reported     |
|                                     |                             | Covishield/Vaxzevria: 1              | Dose 2: 142   |               | 269 NR |                                   |
|                                     |                             | NR: 8                                | NR: 8         |               |        |                                   |
|                                     |                             | BNT162b2: 24 mRNA-1273: 22           | Dose 1: 33    | 55            | 2 M: 1 F | No serious sequelae reported     |
|                                     |                             | Covaxin: 1                           | Dose 2: 13    |               | 43 NR  |                                   |
|                                     |                             | CoronaVac: 2                         | Dose 1: 27    | 60            | 13 M: 15 F | No serious sequelae reported |
|                                     |                             |                                         | Dose 2: 10    |               | 11 NR  |                                   |
|                                     |                             |                                         | NR: 2         |               |        |                                   |
|                                     |                             | BNT162b2: 10 mRNA-1273: 10           | Dose 1: 12    | 79            | 10 M: 10 F | No serious sequelae reported     |
|                                     |                             | CoronaVac: 1                         | Dose 2: 8     |               |        |                                   |
|                                     |                             |                                         |               |               |        |                                   |
|                                     |                             | BNT162b2: 6 mRNA-1273: 12            | Dose 1: 9     | 47            | 0 M: 9 F | No serious sequelae reported     |
|                                     |                             | CoronaVac: 2                         | Dose 2: 9     |               | 9 NR   |                                   |
|                                     |                             |                                         |               |               |        |                                   |
|                                     |                             | BNT162b2: 8 mRNA-1273: 6             | Dose 1: 8     | 70            | 2 M: 2 F | No serious sequelae reported     |
|                                     |                             | CoronaVac: 2                         | Dose 2: 6     |               | 10 NR  |                                   |
|                                     |                             |                                         |               |               |        |                                   |
|                                     |                             | BNT162b2: 7 mRNA-1273: 2             | Dose 1: 5     | 39            | 2M: 4F  | No serious sequelae reported     |
|                                     |                             | CoronaVac: 2                         | Dose 2: 6     |               | 1 NR   |                                   |
|                                     |                             |                                         |               |               |        |                                   |

NR, Not reported.
response stimulated by the vaccine. Given the similarities in the appearance and timing of onset, these delayed local reactions are misdiagnosed as cellulitis.\textsuperscript{10,62} It is important to recognize these reactions to avoid unnecessary antibiotic prescriptions for presumed cellulitis.

Morbilliform eruptions following COVID-19 vaccination were increasingly being reported. The biopsy results demonstrated spongiosis and dermal perivascular lymphocytic infiltrate and were similar to the histochemical results found in the cases of COVID-19–associated cutaneous reactions. They also tended to recur with the second vaccine dose. All these suggested that morbilliform eruptions following COVID-19 vaccination reflect the underlying immune responses generated by the vaccines. Ohsawa et al\textsuperscript{53} suggested that immunity to SARS-CoV-2 would have been established if morbilliform eruptions had developed in patients after they received the initial dose of the vaccine and, therefore, suggested considering omitting the second dose of COVID-19 vaccines.

Following BNT162b2 vaccination, herpes zoster developed in few patients with autoimmune diseases.\textsuperscript{54} In immunocompromized patients, herpes zoster following COVID-19 vaccination may be similar to immune reconstitution inflammatory syndrome. The virus’s reactivation might have been due to the paradoxical worsening of a latent infection unmasked by the host’s inflammatory response to the COVID-19 vaccine. Nonetheless, there are few reports of herpes zoster after COVID-19 vaccination in healthy individuals.\textsuperscript{65-67} Preclinical trials of COVID-19 vaccines demonstrated a transient duration of lymphopenia within the first few days after vaccination.\textsuperscript{37,68} The timing of herpes zoster onset corresponds with that of lymphopenia; therefore, it is conceivable that the transient duration of lymphopenia after COVID-19 vaccination can trigger herpes zoster.

To date, 15 cases of delayed filler reactions after COVID-19 vaccination have been reported across 3 observational studies. Adipose tissue, where most fillers are injected, has a high expression of angiotensin-converting enzyme 2 receptors. Coincidentally, these receptors are targeted by the SARS-CoV-2 spike protein, and the resulting interactions may instigate an inflammatory cascade. This may explain the delayed reaction to hyaluronic acid fillers observed after COVID-19 vaccination. Munavalli et al\textsuperscript{13,69} proposed the use of lisinopril to treat delayed filler reactions after COVID-19 vaccination, which was deemed beneficial. The authors theorized that blocking the production of angiotensin II reduces the angiotensin-converting enzyme 2 substrate; thus, angiotensin-converting enzyme inhibitors can promote an anti-inflammatory response.

There are reported cases of pityriasis rosea eruption following COVID-19 vaccination. One of the hypotheses regarding this association is that a high cytokine response to the vaccine distracts the T-cell–mediated control of latent infections, such as human herpes virus 6 and 7 and, hence, the reactivation of the latent viruses.\textsuperscript{70-72} In contrast, pityriasis rosea-like eruptions following COVID-19 vaccination may have a different pathophysiology. These have been postulated to be a manifestation of a delayed hypersensitivity response to the vaccine.\textsuperscript{73}

This literature review had some limitations. First, the focus of the included clinical trials was predominately on vaccine efficacy; therefore, there was a lack of details regarding cutaneous reactions and participant information. Second, most of the included individuals did not undergo skin biopsy; it was challenging to differentiate causality from causation for some of the cutaneous manifestations without histologic results. Third, a reporting bias could not be excluded.

In conclusion, this review presents a spectrum of cutaneous reactions following COVID-19 vaccination. Most reactions were self-limiting and should not discourage vaccination. We observed that cutaneous reactions following mRNA-based vaccination were more commonly reported than those after inactivated whole-virus vaccination. This might have been due to the widespread use of mRNA-based vaccines. However, the safety of COVID-19 vaccines should continue to be monitored. Accurate and transparent communication with the communities about the adverse events associated with COVID-19 vaccines and their possible causes is important in increasing vaccine acceptance. Further studies with histopathological findings are needed to establish the causality of the skin reactions following vaccinations.

Conflicts of interest

None disclosed.

REFERENCES

1. Chirumbolo S. Vaccination hesitancy and the “myth” on mRNA-based vaccines in Italy in the COVID-19 era: does urgent meet major safety criteria? J Med Virol. 2021;93(7):4049-4053.

2. Hotez P, Batista C, Ergonul O, et al. Correcting COVID-19 vaccine misinformation: lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members. EClinicalMedicine. 2021;33:100780.

3. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615.
4. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416.

5. Ramasamy MN, Minnassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396(10267):1979-1993.

6. Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(6):803-812.

7. McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46-55.

8. Baeck M, Marot L, Belkhir L. Delayed large local reactions to mRNA COVID-19 vaccines. JAMA. 2021;325(15):1562-1565.

9. Blumenthal KG, Robinson LB, Camargo CA, et al. Acute allergic reactions to mRNA COVID-19 vaccines. JAMA. 2021;325(15):e730.

10. Blanchi L, Biondi F, Hansel K, Murgia N, Tramontana M, Stingeni L. Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: limits of intradermal testing. Allergy. 2021;76(8):2605-2607.

11. Minavalli GG, Guthridge J, Knutsen-Larson S, Brodsky A, Matthew E, Landau M. COVID-19 SARS-CoV-2 virus Spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatment. Arch Dermatol Res. 2022;314(1):1-15.

12. Michon A. Hyaluronic acid soft tissue filler delayed inflammatory reaction following COVID-19 vaccination—a case report. J Cosmet Dermatol. 2021;20(9):2684-2690.

13. Dash S, Sirka CS, Mishra S, Viswan P. COVID-19 vaccine-induced Stevens–Johnson syndrome. Clin Exp Dermatol. 2021;46(6):1615-1617.

14. Lospinoso K, Nichols CS, Malachowski SJ, Mochel MC, Nutan F. A case of severe cutaneous adverse reaction following administration of the Janssen Ad26.COV2.S COVID-19 vaccine. J Am Acad Dermatol. 2022;86(1):134-137.

15. Kim MJ, Kim JW, Kim MS, Choi SY, Na Ji. Generalized erythema multiforme-like skin rash following the first dose of COVID-19 vaccine (Pfizer-BioNTech). J Eur Acad Dermatol Venereol. 2022;36(2):e89-1100.

16. Saibene AM, Alliata A, Cozzi AT, et al. Erythema multiforme major following SARS-CoV-2 vaccine. Clin Case Rep. 2021;9(10):e04947.
40. Lieberman P, Simons FE. Anaphylaxis and cardiovascular disease: therapeutic dilemmas. *Clin Exp Allergy*. 2015;45(8):1288-1295.

41. Liu X, Lee S, Lohse CM, Hardy CT, Campbell RL. Biphasic reactions in emergency department anaphylaxis patients: a prospective cohort study. *J Allergy Clin Immunol Pract*. 2020;8(4):1230-1238.

42. Abi Zeid Daou C, Natout MA, El Hadi N. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine. *J Med Virol*. 2021;93(10):6027-6029.

43. Wenande E, Garvey LH. Immediate-type hypersensitivity to polyethylene glycols: a review. *Clin Exp Allergy*. 2016;46(7):907-922.

44. Sellaturay P, Nasser S, Ewan P. Polyethylene glycol-induced systemic allergic reactions (anaphylaxis). *J Allergy Clin Immunol Pract*. 2021;9(2):670-675.

45. Sellaturay P, Nasser S, Islam S, Gurugama P, Ewan PW. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine. *Clin Exp Allergy*. 2021;51(6):861-863.

46. Kounis NG, Koniaris I, de Gregorio C, et al. Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations. *Vaccines (Basel)*. 2021;9(3):221.

47. Bellomo RG, Gallenga CE, Caraffa A, Tetè G, Ronconi G, Conti P. Anaphylaxis is a rare reaction in COVID-19 vaccination. *J Biol Regul Homeost Agents*. 2021;35(3):839-842.

48. Interna clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. Centers for Disease Control and Prevention. Accessed August 7, 2021. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html

49. Park HJ, Montgomery CJ, Boggs LN. Anaphylaxis after the Covid-19 vaccine in a patient with cholinergic urticaria. Preprint. Posted online April 14, 2021. *Mil Med*. https://doi.org/10.1093/milmed/usab138

50. Guidance for differentiating anaphylaxis from acute stress response for vaccine providers and emergency departments. Melbourne Vaccine Education Centre. Accessed August 7, 2021. https://mvec.mcri.edu.au/guidance-for-differentiating-anaphylaxis-from-acute-stress-response-for-vaccine-providers-and-emergency-departments/

51. Gold MS, MacDonald NE, McMurtry CM, et al. Immunization stress-related reaction—redefining immunization anxiety-related reaction as an adverse event following immunization. *Vaccine*. 2020;38(14):3015-3020.

52. Turner PJ, Anstogiul JI, Campbell DE, et al. COVID-19 vaccine-associated anaphylaxis: a statement of the World Allergy Organization Anaphylaxis Committee. *World Allergy Organ J*. 2021;14(2):100517.

53. McNeil MM, Weintraub ES, Duffy J, et al. Risk of anaphylaxis after vaccination in children and adults. *J Allergy Clin Immunol*. 2016;137(3):868-878.

54. Paul E, Steptoe A, Fancourt D. Attitudes towards vaccines and intention to vaccinate against COVID-19: implications for public health communications. *Lancet Reg Health Eur*. 2021;1:100012.

55. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *Lancet*. 2021;397(10287):1819-1829.

56. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. *N Engl J Med*. 2021;384(15):1412-1423.

57. Zhang Y, Cao W, Xiao M, et al. Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acute ischemia. *Zhonghua Xue Ye Xue Za Zhi*. 2020;41(4):302-307.

58. Wei N, Fishman M, Wattenberg D, Gordon M, Lebowohl M. “COVID arm”: a reaction to the Moderna vaccine. *JAAD Case Rep*. 2021;10:92-95.

59. Grobusch MP, Schnyder J, Garcia-Garrido HM, et al. Delayed large local reaction to the adenosine-vectored (ChAdOx1) vaccine. *Trev Med Infect Dis*. 2021;43:102093.

60. Ewer KJ, Barrett JR, Belij-Rammerstorfer S, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 vaccine in a phase 1/2 clinical trial. *Nat Med*. 2021;27(2):270-278.

61. Meibnerger D, Koch M, Roth A, et al. Analysis of IgM, IgA, and IgG isotype antibodies directed against SARS-CoV-2 spike glycoprotein and ORF8 in the course of COVID-19. *Sci Rep*. 2021;11(1):1-9.

62. Blumenthal KG, Freeman EE, Saff RR, et al. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2. *N Engl J Med*. 2021;384(13):1273-1277.

63. Ohsawa R, Sano H, Ikeda M, Sano S. Clinical and histopathological views of morbilliform rash after COVID-19 mRNA vaccination mimicking those in SARS-CoV-2 virus infection-associated cutaneous manifestations. *J Dermatol Sci*. 2021;103(2):124-127.

64. Furer V, Zisman D, Kibari A, Rimar D, Paran Y, Elkayam O. Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. *Rheumatology (Oxford)*. 2021;60(S1):S190-S195.

65. Bostan E, Yalici-Armagan B. Herpes zoster following inactivated COVID-19 vaccine: a coexistence or coincidence? *J Cosmet Dermatol*. 2021;20(6):1566-1567.

66. Eid E, Abdullah L, Kurban M, Abbas O. Herpes zoster emergence following mRNA COVID-19 vaccine. *J Med Virol*. 2021;93(9):5231-5232.

67. Lee C, Cotter D, Basa J, Greenberg HL. 20 Post-COVID-19 vaccine-related shingles cases seen at the Las Vegas Dermatology clinic and sent to us via social media. *J Cosmet Dermatol*. 2021;20(7):1960-1964.

68. Mulligan MJ, Lyke KE, Kitchin N, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. *Nature*. 2020;586(7830):589-593.

69. Munavalli GG, Knutzen-Larson S, Lupo MP, Geronemus RG. Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination—a model for inhibition of angiotensin II-induced cutaneous inflammation. *JAAD Case Rep*. 2021;10:63-68.

70. Drago F, Ciccaccese G, Rebora A, Parodi A. Pityriasis rosea resembling human papillomavirus vaccination. *Braz J Infect Dis*. 2015;19(2):224-225.

71. Watanabe T, Kawamura T, Aquilano EA, et al. Pityriasis rosea is associated with systemic active infection with both human herpesvirus-7 and human herpesvirus-6. *J Invest Dermatol*. 2002;119(4):793-797.

72. Drago F, Broccolo F, Rebora A. Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology. *J Am Acad Dermatol*. 2009;61(2):303-318.

73. Wilkin JK, Kirkendall WM. Pityriasis rosea-like rash from captopril. *Arch Dermatol*. 1982;118(3):186-187.